Robert Reddig, MD
Neurology · Kansas City, MONPI 1538105754
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $112,659 of the $129,170 with a category attached, or 87.2%. AbbVie accounts for 79.1% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $32,619 and has fallen 58.0% since, to $13,688 in 2025. Among neurology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 364 payments — averaging $354.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$102K
- Eisai Inc.$14K
- Pfizer$11K
- Lilly USA, LLC$254
- UCB, Inc.$222
- Teva Pharmaceuticals USA, Inc.$193
- plus $1K from 24 others
What the payments were for
- Consulting fees$9,5987%
- Speaking & faculty fees$112,65987%
- Travel & lodging$2,2292%
- Food & beverage$4,6344%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 227 | $102,226 |
| Eisai Inc. | 30 | $13,783 |
| Pfizer | 20 | $11,265 |
| Lilly USA, LLC | 8 | $254 |
| UCB, Inc. | 11 | $222 |
| Teva Pharmaceuticals USA, Inc. | 11 | $193 |
| AstraZeneca(2 entities) | 2 | $132 |
| Amgen | 5 | $132 |
| Jazz Pharmaceuticals Inc. | 6 | $127 |
| SK Life Science, Inc. | 5 | $116 |
| Lundbeck LLC | 4 | $82 |
| Kyowa Kirin, Inc. | 4 | $77 |
| Neurocrine Biosciences, Inc. | 4 | $70 |
| Argenx US, Inc. | 2 | $61 |
| Amneal Pharmaceuticals LLC | 3 | $58 |
| Supernus Pharmaceuticals, Inc. | 2 | $44 |
| Novartis | 3 | $44 |
| Acadia Pharmaceuticals Inc | 3 | $43 |
| Impel Pharmaceuticals Inc. | 2 | $33 |
| Acorda Therapeutics, Inc | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $23 |
| Harmony Biosciences LLC | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 2 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Promius Pharma LLC | 1 | $16 |
| Avion Pharmaceuticals | 1 | $16 |
| Medtronic | 1 | $15 |
| GE HealthCare | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$129,170 in reported general payments places this provider in the 90th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 22 | $26,619 |
| ZavzpretZavegepant Hcl | 11 | $11,501 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 121 | $4,044 |
| Levetiracetam | 79 | $3,493 |
| Lacosamide | 18 | $2,900 |
| Gabapentin | 90 | $2,552 |
| Primidone | 95 | $1,593 |
| Entacapone | 11 | $1,559 |
| Pregabalin | 28 | $1,397 |
| Sumatriptan Succinate | 16 | $1,271 |
| Propranolol Hcl | 64 | $1,100 |
| Memantine Hcl | 70 | $1,041 |
| Donepezil Hcl | 124 | $934 |
| Propranolol Hcl ErPropranolol Hcl | 19 | $722 |
| Topiramate | 38 | $530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta | $102,226 | $26,61922 claims |
| PfizerZavzpret | $11,265 | $11,50111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 381 neurology providers in Missouri.
Other neurology in Kansas City
- Stanley FisherKansas City$155K
- Rola MahmoudKansas City$155K
- Samuel GoldlustKansas City$124K
- Brooke HeffernanKansas City$27K
- Susan SifersKansas City$25K
- William RosenfeldChesterfield$2.1M
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Curtis SchreiberBolivar$882K
- Robert NaismithSaint Louis$677K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.